Top Page
Perimeter Medical Imaging AI
(PINK)
Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)
Perimeter Medical Imaging AI Business Overview & Revenue Model
Perimeter Medical Imaging AI Earnings Call Summary
Perimeter Medical Imaging AI Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 846.19K | 403.53K | 132.77K | 11.34K | 0.00 |
| Gross Profit | 535.11K | 206.42K | 100.63K | 5.04K | -47.57K |
| EBITDA | -12.64M | -17.92M | -11.72M | -15.95M | -6.11M |
| Net Income | -13.39M | -18.94M | -3.59M | -16.76M | -8.00M |
Balance Sheet | |||||
| Total Assets | 14.33M | 27.09M | 34.60M | 9.98M | 13.16M |
| Cash, Cash Equivalents and Short-Term Investments | 6.18M | 18.43M | 28.44M | 5.14M | 11.70M |
| Total Debt | 137.48K | 192.89K | 325.68K | 441.17K | 400.81K |
| Total Liabilities | 3.87M | 7.10M | 8.49M | 2.56M | 2.40M |
| Stockholders Equity | 10.45M | 15.06M | 26.11M | 7.42M | 10.76M |
Cash Flow | |||||
| Free Cash Flow | -16.90M | -15.17M | -13.86M | -16.03M | -8.26M |
| Operating Cash Flow | -14.72M | -14.70M | -11.87M | -13.91M | -8.26M |
| Investing Cash Flow | -1.90M | 206.01K | -1.75M | -1.45M | 7.24M |
| Financing Cash Flow | 8.58M | 234.47K | 40.28M | 10.06M | 9.84M |
Perimeter Medical Imaging AI Technical Analysis
Perimeter Medical Imaging AI Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | C$118.60M | ― | -9.96% | ― | -0.70% | -102.48% | |
60 Neutral | C$23.65M | ― | -23.87% | ― | 18.97% | 17.57% | |
54 Neutral | C$226.60M | ― | -66.14% | ― | 80.62% | 3.55% | |
51 Neutral | $7.44B | -0.20 | -46.00% | 2.26% | 22.80% | -2.27% | |
49 Neutral | C$26.74M | ― | -163.62% | ― | 245.01% | -4.91% | |
48 Neutral | C$56.43M | ― | -291.48% | ― | -8.63% | 7.04% | |
44 Neutral | C$19.20M | ― | 207.08% | ― | 267.59% | 2.33% |
Perimeter Medical Imaging AI Corporate Events
Perimeter Medical Imaging AI, Inc. has successfully closed the final tranche of its prospectus offering, raising a total of approximately $5.35 million. The funds will be used to advance the commercialization of their technology, establish clinical evidence, and continue product development, which could strengthen their market position and benefit stakeholders by enhancing their innovative imaging solutions for cancer surgery.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Medical City Dallas Hospital has adopted Perimeter Medical Imaging AI’s S-Series OCT technology for high-resolution tissue visualization during surgeries. This adoption follows the hospital’s participation in a pivotal trial of Perimeter’s B-Series device, which integrates AI and is under FDA evaluation for breast-conserving surgeries. The S-Series OCT, cleared by the FDA in 2021, offers cellular-level imaging, making it ideal for surgical margin visualization. This deployment marks a significant step in Perimeter’s nationwide technology rollout, potentially enhancing surgical outcomes and positioning the company as a leader in advanced medical imaging solutions.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced that its CEO, Adrian Mendes, will present an update on the company’s business at the Life Sciences Virtual Investor Forum. This presentation reflects Perimeter’s ongoing efforts to enhance its industry positioning by showcasing its innovative imaging technologies, which aim to address unmet medical needs in cancer surgery.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry to collect images and data from surgeries using their imaging technology. This initiative aims to enhance their AI deep-learning model for investigational technology, potentially improving surgical outcomes and reducing the need for second surgeries. The registry will help in developing a sophisticated AI model by gathering diverse data, which could lead to more personalized patient care and better clinical results.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI, Inc. has successfully closed its prospectus offering, raising approximately $3.13 million through the issuance of over 10 million units. The proceeds will support the commercialization of its technology, clinical evidence establishment, and product development. This financial move is expected to bolster Perimeter’s market position and operational capabilities, potentially enhancing its impact on the medical imaging industry.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI, Inc. has announced the pricing and terms of its public offering of units, aiming to raise at least $2.5 million through the issuance of a minimum of 8,333,334 securities. The proceeds will be used to further commercialize its technology and support product development, with the offering expected to attract U.S. institutional investors and company insiders. The offering is subject to regulatory approvals and is expected to close on or around June 3, 2025, with the potential to raise up to $15 million in total.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI has partnered with Intermountain Health to explore the clinical, social, and economic benefits of using its OCT and AI technologies to reduce cancer reoperations. This collaboration will initially involve a study on breast-conserving surgery reoperation rates and costs, potentially shaping Perimeter’s commercial and market access strategies. The partnership underscores the commitment to innovation in surgical oncology, with implications for improving patient and provider experiences and expanding the technology’s application beyond breast tissue.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI reported record revenue for the first quarter of 2025, driven by significant commercial traction of its FDA-cleared Perimeter S-Series device. The company achieved several commercial milestones, including increased case volumes and substantial billings. Additionally, Perimeter is advancing its next-generation Perimeter B-Series device, which incorporates AI technology, and has submitted a Premarket Approval application to the FDA. The pivotal trial results for the B-Series, presented at the American Society of Breast Surgeons meeting, showed promising outcomes, potentially transforming surgical practices by improving intraoperative decision-making and reducing re-excisions.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced it will release its first quarter 2025 financial results on May 13, 2025, followed by a webcast and conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it offers stakeholders insights into the company’s financial health and operational progress, potentially impacting its market positioning and future strategic decisions.
Perimeter Medical Imaging AI announced successful results from a pivotal trial of its B-Series OCT with ImgAssist AI 2.0, presented at the American Society of Breast Surgeons 2025 meeting. The trial demonstrated a statistically significant reduction in residual cancer during surgery, meeting its primary endpoint and showcasing the device’s potential to improve surgical outcomes by reducing re-excisions and enhancing intraoperative decision-making. The company has submitted a Premarket Approval application to the FDA, marking a significant milestone in its regulatory journey.